Science in Service of People
Matota Technologies was founded on the belief that better imaging tools can lead to faster, more informed decisions in drug development — and that those decisions ultimately affect real people waiting on research to translate into treatment.
Shorten the Path from Discovery to Patient
Our mission is to shorten the path between scientific discovery and patient access. We develop scientific imaging tools designed to help drug-development teams observe biological responses faster, make experimental decisions sooner, and move promising therapies forward more efficiently.
Grounded in Peer-Reviewed Research
The CSOD platform originates from peer-reviewed research in optical and biological imaging. Matota Technologies was founded to translate that scientific work into a compact, laboratory-compatible instrument — making schlieren-based biological imaging accessible to the broader research community.
Validated by Independent Literature
Academic literature supports the premise that biological events can be detected through physical-property changes rather than only through labels, stains, or endpoint biochemical assays. Magnetic levitation studies show that single cells and microorganisms have measurable density-linked profiles, including changes associated with drug treatment. Digital holographic microscopy studies further show that nanoparticle and cytotoxic perturbations can be quantified through label-free optical measurements of native cell populations. Together, these studies validate the scientific basis for CSOD: biological response can produce measurable physical changes, and those changes can serve as event indicators.
Durmus et al., 2015 — density-linked cellular event detection via magnetic levitation
Delikoyun et al., 2021 — density-based cell analysis integrated with label-free imaging
Eder et al., 2022 — label-free optical quantification of nanoparticle cytotoxicity
Marzi et al., 2022 — interlaboratory DHM evaluation of polymeric nanocarriers
Carpenter, 2010 — high-content imaging as a bottleneck in drug-screening workflows
Not Every Delay Is Inevitable
Drug development is inherently complex, but every avoidable delay extends the time patients wait for new therapies. Matota Technologies develops tools designed to make research workflows more efficient and accelerate experimental decision-making. Patients should benefit from medical innovation sooner. We are working to help make that possible.
Our mission is to shorten the path between scientific discovery and patient access.
Our Principles
We build on defensible science
The CSOD is grounded in peer-reviewed research and validated scientific premises. We communicate what we have built and what we are testing — not what we hope to eventually claim.
We design for the researcher
The CSOD is being designed around the real needs of biological researchers — compact, workflow-compatible, and oriented toward actionable experimental feedback.
We build for access, not just performance
Advanced optical imaging should not require large-scale infrastructure. We are building for the laboratories that need better tools, not just the ones that already have them.
We measure success by patient impact
Faster experimental decisions mean faster development timelines. Faster development timelines mean patients reach effective therapies sooner. That is the standard we hold ourselves to.
Interested in Matota Technologies?
We welcome inquiries from researchers, institutions, investors, and potential collaborators.